Twist Bioscience (NASDAQ:TWST) CFO Sells $165,000.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 3,000 shares of the stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00. Following the completion of the sale, the chief financial officer directly owned 122,694 shares in the company, valued at approximately $6,748,170. This represents a 2.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adam Laponis also recently made the following trade(s):

• On Thursday, April 9th, Adam Laponis sold 2,597 shares of Twist Bioscience stock. The shares were sold at an average price of $49.89, for a total transaction of $129,564.33.
• On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00.

Twist Bioscience Trading Down 2.4%

Shares of TWST traded down $1.39 during midday trading on Thursday, hitting $56.23. The stock had a trading volume of 1,426,461 shares, compared to its average volume of 1,306,249. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $59.90. The firm has a market cap of $3.45 billion, a PE ratio of -43.93 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The stock’s 50 day moving average is $48.26 and its 200 day moving average is $38.73.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million during the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience’s quarterly revenue was up 16.9% compared to the same quarter last year. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stifel Financial Corp grew its holdings in Twist Bioscience by 3.6% during the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after acquiring an additional 271 shares in the last quarter. D.A. Davidson & CO. grew its holdings in Twist Bioscience by 1.2% during the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after acquiring an additional 305 shares in the last quarter. CWM LLC grew its holdings in Twist Bioscience by 9.4% during the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after acquiring an additional 407 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares in the last quarter. Finally, California State Teachers Retirement System grew its holdings in Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after acquiring an additional 442 shares in the last quarter.

Wall Street Analyst Weigh In

TWST has been the subject of a number of research analyst reports. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Evercore lifted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Barclays lifted their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $47.13.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.